Clinical Trials on Extramedullary Myeloma

Total 7177 results

City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Juno Therapeutics, Inc.

Completed

Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
University of Southern California
National Cancer Institute (NCI); Oncolytics Biotech

Completed

Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Dana-Farber Cancer Institute
Bristol-Myers Squibb; Celgene; The Leukemia and Lymphoma Society; Multiple Myeloma... and other collaborators

Completed

E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma | Smoldering Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma

Smoldering Plasma Cell Myeloma

United States
Yvonne Efebera
Bristol-Myers Squibb; National Cancer Institute (NCI); American Cancer Society...

Terminated

Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Completed

AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Terminated

Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma

United States, South Africa
NYU Langone Health
Unicorn Pacific Corporation

Terminated

A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma

Myeloma

United States
Jules Bordet Institute
RayzeBio, Inc.

Not yet recruiting

A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors (AcTRESS)

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Multiple Myeloma Progression

Belgium
Carl Ola Landgren, MD, PhD
Janssen Scientific Affairs, LLC

Recruiting

Teclistamab or Talquetamab in Combination With Daratumumab for High-Risk Smoldering Myeloma (REVIVE Study) (REVIVE)

Multiple Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Harpoon Therapeutics

Active, not recruiting

A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM

Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma of Bone

United States, France, Spain
Roswell Park Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic

Completed

Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Sanofi

Active, not recruiting

A Phase 3 Randomized, Open-label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smoldering Multiple Myeloma

Plasma Cell Myeloma

Italy, Korea, Republic of, Norway, Canada, Spain, Germany, Greece, Lithuania, Sweden, Israel, Hungary, France, Japan, Australia, China, Denmark, Czechia, Turkey, United States, Brazil, Ireland, New Zealand, Poland, United Kingdom
Fred Hutchinson Cancer Center
The Leukemia and Lymphoma Society; Juno Therapeutics, Inc., a Bristol-Myers...

Terminated

BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH); Millennium... and other collaborators

Active, not recruiting

Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Completed

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Withdrawn

Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Completed

Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Jagannath, Sundar, M.D.
Unicorn Pacific Corporation

Terminated

Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic Myeloma

Multiple Myeloma

United States
University of Utah
Millennium Pharmaceuticals, Inc.

Terminated

Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients

Cancer | Multiple Myeloma | Myeloma

United States
Masonic Cancer Center, University of Minnesota
Minnesota Medical Foundation

Terminated

Preservation of Ovarian Function After Hematopoietic Cell Transplant

Acute Myeloid Leukemia | Myeloproliferative Disorders | Multiple Myeloma | Hodgkin Disease | Non-Hodgkin Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Acute Myeloid Leukemia | Recurrent Hodgkin Lymphoma | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma | Aplastic Anemia | Recurrent Non-Hodgkin... and other conditions

United States
Hospital Clinic of Barcelona
Instituto de Salud Carlos III; European Union

Completed

Prevention of Left Ventricular Dysfunction During Chemotherapy (OVERCOME)

Lymphoma | Acute Myeloid Leukemia | Multiple Myeloma | Lymphoid Neoplasm | Autologous Hematopoietic Stem Cell Transplantation | Precursor-cell Lymphoblastic Leukemia-Lymphoma

Spain
MedImmune LLC

Completed

A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Diffuse Large B-cell Lymphoma

United States, France, Korea, Republic of
Cantonal Hospital of St. Gallen
University Hospital, Geneva; University Hospital Muenster; Stanford University; University of Toronto and other collaborators

Recruiting

Microsurgical Resection of Intramedullary Spinal Cord Metastases

Spinal Cord Neoplasms | Radiotherapy; Complications | Functional Outcome | Spinal Cord Metastasis | Spinal Cord Tumor Malignant Intramedullary

Switzerland
Roswell Park Cancer Institute
Celgene

Active, not recruiting

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Plasma Cell Myeloma | Partial Response of Multiple Myeloma or Plasma Cell Leukemia

United States
Case Comprehensive Cancer Center

Withdrawn

Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma

Myeloma | Smoldering Myeloma | Monoclonal Gammopathy

United States
National Cancer Institute (NCI)

Terminated

Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)

Monoclonal Gammopathy of Undetermined Significance | Smoldering Myeloma

United States
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Hematopoietic Cell Transplantation Recipient

United States
The Cleveland Clinic

Withdrawn

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Plasma Cell Neoplasm

United States
National Cancer Institute (NCI)

Withdrawn

Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | t(11;14) Negative
Virginia Commonwealth University
National Cancer Institute (NCI)

Completed

High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies

Lymphoma | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Drug/Agent Toxicity by Tissue/Organ

United States
Pfizer

Active, not recruiting

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Multiple Myeloma | Refractory Multiple Myeloma | Myeloma | Relapsed Multiple Myeloma | Elranatamab | PF-06863135 | BCMA | Bispecific | Bispecific Antibody | BCMA-CD3 Bispecific | MagnetisMM-8

China
Rennes University Hospital
Intergroupe Francophone du Myelome

Terminated

Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma Cells From MGUS and SMM. (GENOMGUS)

Monoclonal Gammopathy of Undetermined Significance | Smoldering Myeloma

France
Caribou Biosciences, Inc.

Enrolling by invitation

Long-Term Follow-up Study (LTFS)

Lymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Hematologic Malignancy | Relapsed/Refractory Multiple Myeloma | Relapsed/Refractory Acute Myeloid Leukemia | Relapsed Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin's Lymphoma

United States
Melbourne Health

Recruiting

Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation (VICTORY)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Plasma Cell Myeloma | Non-hodgkin Lymphoma | Leukemia, Lymphoblastic, Acute, L1 | Leukemia, Lymphoblastic, Acute, L2

Australia
National Cancer Institute (NCI)

Completed

Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant

Recurrent Hodgkin Lymphoma | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Recurrent Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Plasma Cell Myeloma | Myeloproliferative Neoplasm | Recurrent... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Hodgkin Lymphoma | Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Acute Leukemia | Myelodysplastic Syndrome | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Myeloproliferative... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

Refractory Plasma Cell Myeloma | Plasmacytoma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia

United States
Nantes University Hospital

Not yet recruiting

Evaluation of a Range of Dermo-cosmetic Products to Treat Skin and Nail Toxicity Linked to Bispecific Anti-GPRC5D Bispecific Antibodies in Multiple Myeloma Patients". Myeloma". Descriptive Pilot Study (DELICATESSE)

Myeloma Multiple

Clinical Trials on Extramedullary Myeloma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations